Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nonalcoholic Steatohepatitis Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Key Product/ Brand Analysis
5.2. Key industry events (mergers, acquisitions, product launches etc.)
5.3. Technological Advancements
5.4. Regulatory Scenario, by Region/ Globally
5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Obeticholic Acid (OCA)
6.3.2. Aramchol (arachidyl amido cholanoic acid)
6.3.3. Saroglitazar
6.3.4. Elafibranor
6.4. Market Attractiveness By Drug Type

7. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region

8. North America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Drug Type, 2017–2031
8.2.1. Obeticholic Acid (OCA)
8.2.2. Aramchol (arachidyl amido cholanoic acid)
8.2.3. Saroglitazar
8.2.4. Elafibranor
8.3. Market Value Forecast, by Country, 2017–2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Drug Type
8.4.2. By Country

9. Europe Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017–2031
9.2.1. Obeticholic Acid (OCA)
9.2.2. Aramchol (arachidyl amido cholanoic acid)
9.2.3. Saroglitazar
9.2.4. Elafibranor
9.3. Market Value Forecast, by Country/Sub-region, 2017–2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Drug Type
9.4.2. By Country/Sub-region

10. Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Obeticholic Acid (OCA)
10.2.2. Aramchol (arachidyl amido cholanoic acid)
10.2.3. Saroglitazar
10.2.4. Elafibranor
10.3. Market Value Forecast, by Country/Sub-region, 2017–2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Drug Type
10.4.2. By Country/Sub-region

11. Latin America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Obeticholic Acid (OCA)
11.2.2. Aramchol (arachidyl amido cholanoic acid)
11.2.3. Saroglitazar
11.2.4. Elafibranor
11.3. Market Value Forecast, by Country/Sub-region, 2017–2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Drug Type
11.4.2. By Country/Sub-region

12. Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Obeticholic Acid (OCA)
12.2.2. Aramchol (arachidyl amido cholanoic acid)
12.2.3. Saroglitazar
12.2.4. Elafibranor
12.3. Market Value Forecast, by Country/Sub-region, 2017–2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Drug Type
12.4.2. By Country/Sub-region

13. Competition Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis By Company (2021)
13.3. Company Profiles
13.3.1. F. Hoffmann-La Roche
13.3.1.1. Company Overview (HQ, Business Segments, Employee)
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Strategic Overview
13.3.2. Siemens Healthineers AG.
13.3.2.1. Company Overview (HQ, Business Segments, Employee)
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Strategic Overview
13.3.3. Thermo Fisher Scientific
13.3.3.1. Company Overview (HQ, Business Segments, Employee)
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Strategic Overview
13.3.4. Danaher Corporation
13.3.4.1. Company Overview (HQ, Business Segments, Employee)
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Strategic Overview
13.3.5. Bio-Rad Laboratories
13.3.5.1. Company Overview (HQ, Business Segments, Employee)
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Strategic Overview
13.3.6. Abbott Laboratories
13.3.6.1. Company Overview (HQ, Business Segments, Employee)
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Strategic Overview
13.3.7. Alpco
13.3.7.1. Company Overview (HQ, Business Segments, Employee)
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Strategic Overview
13.3.8. Beckman Coulter Inc.
13.3.8.1. Company Overview (HQ, Business Segments, Employee)
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Strategic Overview
13.3.9. Chromsystems Instrume
13.3.9.1. Company Overview (HQ, Business Segments, Employee)
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Strategic Overview
13.3.10. Pharmaceutical Drug Type Development LLC
13.3.10.1. Company Overview (HQ, Business Segments, Employee)
13.3.10.2. Product Portfolio
13.3.10.3. SWOT Analysis
13.3.10.4. Strategic Overview
13.3.11. Randox Laboratories Ltd.
13.3.11.1. Company Overview (HQ, Business Segments, Employee)
13.3.11.2. Product Portfolio
13.3.11.3. SWOT Analysis
13.3.11.4. Strategic Overview
13.3.12. Other prominent players
13.3.12.1. Company Overview (HQ, Business Segments, Employee)
13.3.12.2. Product Portfolio
13.3.12.3. SWOT Analysis
13.3.12.4. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031

Figure 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031

Figure 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031

Figure 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 13: Global Nonalcoholic Steatohepatitis Therapeutics Market Share Analysis, by Company (2021)

List of Tables

List of Tables

Table 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031

Table 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031

Table 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031